134 related articles for article (PubMed ID: 27304949)
1. Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold.
Wang L; Liu F; Jiang N; Zhou W; Zhou X; Zheng Z
Molecules; 2016 Jun; 21(6):. PubMed ID: 27304949
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
Molecules; 2019 May; 24(10):. PubMed ID: 31108884
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of 1H-benzo[d]imidazole-4-carboxamide PARP-1 inhibitors using different saturated nitrogen-contained heterocycle as linker group.
Wu K; Peng X; Li Y; Chen M; Liu Y; Liu D; Jiang L; He Y; Peng J; Cao X
Chem Biol Drug Des; 2023 Jun; 101(6):1335-1347. PubMed ID: 36752693
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.
Chen M; Huang H; Wu K; Liu Y; Jiang L; Li Y; Tang G; Peng J; Cao X
Drug Dev Res; 2022 Feb; 83(1):55-63. PubMed ID: 34151456
[TBL] [Abstract][Full Text] [Related]
7. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity.
Zhou J; Ji M; Zhu Z; Cao R; Chen X; Xu B
Eur J Med Chem; 2017 May; 132():26-41. PubMed ID: 28340412
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of phthalazinone thiohydantoin-based derivative as potent PARP-1 inhibitors.
Zhong Y; Meng Y; Xu X; Zhao L; Li Z; You Q; Bian J
Bioorg Chem; 2019 Oct; 91():103181. PubMed ID: 31404795
[TBL] [Abstract][Full Text] [Related]
12. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Chadha N; Jaggi AS; Silakari O
Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
[TBL] [Abstract][Full Text] [Related]
14. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Almahli H; Hadchity E; Jaballah MY; Daher R; Ghabbour HA; Kabil MM; Al-Shakliah NS; Eldehna WM
Bioorg Chem; 2018 Apr; 77():443-456. PubMed ID: 29453076
[TBL] [Abstract][Full Text] [Related]
15. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
16. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.
Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Kerrigan F; Loh VM; Martin NM; Menear KA; Smith GC
Bioorg Med Chem Lett; 2006 Feb; 16(4):1040-4. PubMed ID: 16290932
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel PARP-1 inhibitors based on pyridopyridazinone scaffold.
Elmasry GF; Aly EE; Awadallah FM; El-Moghazy SM
Bioorg Chem; 2019 Jun; 87():655-666. PubMed ID: 30952061
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 5-fluoro-1H-benzimidazole-4-carboxamide derivatives as potent PARP-1 inhibitors.
Wang J; Wang X; Li H; Ji D; Li Y; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2016 Aug; 26(16):4127-32. PubMed ID: 27353531
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
20. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]